Optimi Health (OPTI) Investor presentation summary

Investment highlights and market opportunity

• Revenue-generating since Q2 2024, with nearly 5,000 doses shipped globally and clinical supply added in the UK in 2026.

• Vertically integrated, cGMP-certified facility with Health Canada Drug Establishment License and FDA Establishment Identifier.

• Focus on natural psilocybin and MDMA, with ibogaine in development for PTSD, TRD, opioid addiction, and traumatic brain injuries.

• Positioned to supply new markets as global rescheduling of psychedelics accelerates, with active commercial operations in Australia and limited access in Canada and Switzerland.

• Addressing large unmet needs: over 100 million with TRD and 300 million with PTSD worldwide.

Product portfolio and distribution

• Offers naturally extracted psilocybin capsules (1 mg, 2 mg, 5 mg) and synthetic MDMA capsules (40 mg, 60 mg), both supplied to clinics in Australia and Canada.

• Standardized, pharmaceutical-grade products enable controlled dosing and clinical research.

• Direct-to-clinic model with international export permits and local pharmacy delivery, ensuring compliant and scalable distribution.

• Ibogaine finished-dose development commenced in June 2026, targeting additional indications.

Regulatory and industry landscape

• Benefiting from global policy shifts: Australia rescheduled MDMA and psilocybin in 2023, US Executive Order in 2026 fast-tracks psychedelic research and access.

• Canadian Bill C-286 and EU developments create further market opportunities.

• Competitive advantage as a licensed exporter with multi-year product stability and regulatory compliance.